Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide DDI with Digoxin and Rosuvastatin in Prostate Cancer
NCT04094519Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Jan 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enzalutamide in prostate cancer (PCa), sponsored by Astellas Pharma. Primary endpoints: Pharmacokinetics of Digoxin in combination with rosuvastatin in plasma: maximum concentration, Pharmacokinetics of Digoxin in combination with rosuvastatin in plasma: area under the concentration-time curve from dosing to last measurable concentration and 1 more. Started Jan 2020; status: completed.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04094519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04094519.